ALLOX
ALLOX is a techbio company revolutionizing drug discovery by harnessing genetics and AI to uncover biophysical parameters governing protein function, focusing on allosteric sites. Their proprietary experimental and computational platforms enable high-throughput mutagenesis and machine learning to map protein transition states, exemplified by their large-scale study of Alzheimer's disease-related peptide aggregation. The company operates as a spin-off from Allostery Exploration Technologies S.L., based in Barcelona, and collaborates with pharma and biotech sectors to maximize the transformative potential of their technology. Their approach is innovative, scalable, and positioned to impact neurodegenerative disease treatment development.
ALLOX
ALLOX is a techbio company revolutionizing drug discovery by harnessing genetics and AI to uncover biophysical parameters governing protein function, focusing on allosteric sites. Their proprietary experimental and computational platforms enable high-throughput mutagenesis and machine learning to map protein transition states, exemplified by their large-scale study of Alzheimer's disease-related peptide aggregation. The company operates as a spin-off from Allostery Exploration Technologies S.L., based in Barcelona, and collaborates with pharma and biotech sectors to maximize the transformative potential of their technology. Their approach is innovative, scalable, and positioned to impact neurodegenerative disease treatment development.